THE Government has confirmed that it will bring in a value-based system for deciding the price of new medicines but has yet to decide which additional factors, beyond cost and clinical effectiveness, will become part of the equation. Paying higher prices for new drugs for serious diseases that currently have the "highest unmet need" was generally welcomed, according to a summary of responses to the Government's consultation on its proposals, which was published earlier this week. There was general support for the principle of paying more for new drugs that deliver a step change in treatment.
展开▼
